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Introduction {#sec1}
============

Mitochondrial functions are governed by alterations in nuclear gene expression, adapting them to cellular demands. Under conditions of low oxygen tension, the respiratory chain undergoes a dynamic exchange of selected structural subunits that is governed by altered gene expression initiated by the transcription factor HIF-1 ([@bib16]). The cellular abundance of HIF-1α is regulated by an oxygen-dependent hydroxylation process, catalyzed by prolyl-4-hydroxylase domain enzymes (PHD1--3). These enzymes target HIF-1α to proteasomal degradation. In hypoxia, diminished hydroxylation and concomitant inhibition of turnover stabilize HIF-1α, leading to increased protein amounts. HIF-1 is a master transcriptional regulator that adapts cellular metabolism to conditions of low oxygen, thereby stimulating glycolytic metabolism and altering the composition of mitochondrial oxidative phosphorylation complexes in the inner membrane. In addition to the composition of individual complexes, the organization of the respiratory chain into supercomplexes has been found to dynamically respond to physiological challenges, providing another regulatory level ([@bib17], [@bib19]). Moreover, the activity of individual complexes can be modulated by phosphorylation, allosteric interactions, and exchange of individual subunits in response to oxygen-sensitive gene expression processes that depend on HIF-1 activity, as described above ([@bib2], [@bib31]).

The regulation of mitochondrial metabolism is critical for cellular functions and differs significantly between tissues and environmental conditions. In the case of the heart, mitochondria provide 90% of the energy demand by oxidative phosphorylation ([@bib42]). Accordingly, defects in mitochondrial functions are frequently linked to human disorders. One example is Barth syndrome, which represents a severe X-linked cardiomyopathy caused by mutations in the TAZ gene, encoding the mitochondrial transacylase tafazzin ([@bib4]). Tafazzin facilitates cardiolipin remodeling, converting monolysocardiolipin to a mature cardiolipin molecule with distinct unsaturated fatty acid side chain composition. This altered lipid composition affects inner membrane morphology as well as activity and organization of the oxidative phosphorylation system. Because respiratory chain supercomplexes, formed by complexes I, III, and IV ([@bib45]), are structurally dependent on interactions with cardiolipin, they are destabilized in Barth syndrome models ([@bib14], [@bib15], [@bib33]).

To this end, anterograde signaling processes that adapt mitochondrial function through proteomic adaptation are well established. However, it is still ill defined as to how mitochondria are able to affect nuclear gene expression upon an altered metabolic state (e.g., in the case of changes in the oxidative phosphorylation capacity, in a retrograde manner to adapt nuclear gene expression).

Results and Discussion {#sec2}
======================

Tafazzin-Deficient Cells Display Reduced Levels and Activity of HIF-1α {#sec2.1}
----------------------------------------------------------------------

To investigate the consequences of a loss of tafazzin on mitochondrial and cellular functions, we used CRISPR/Cas9-mediated gene editing to disrupt the TAZ gene in mouse embryonic fibroblasts (MEFs). The correct targeting of the TAZ gene and the mutations that were caused were confirmed by sequencing of the genomic locus ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Because reliable antibodies against mouse tafazzin are not available, we confirmed loss of tafazzin function in TAZ^KO^ cells by mass spectrometry to demonstrate that these cells displayed reduced cardiolipin levels and the concomitant increase in monolysocardiolipin (MLCL) ([Figure 1](#fig1){ref-type="fig"}A) characteristic of TAZ deficiency ([@bib21]). Consistent with a shift in the mitochondrial cardiolipin pool, isolated TAZ^KO^ mitochondria showed a destabilization of respiratory chain supercomplexes and a reduction of the mitochondrial membrane potential ([Figures S1](#mmc1){ref-type="supplementary-material"}C--S1E), as observed before in diverse Barth syndrome models ([@bib7], [@bib14], [@bib29], [@bib33]). On glucose-containing medium, TAZ^KO^ cells displayed a mild growth defect that was exacerbated on respiratory medium ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}F). The enzymatic activity of the respiratory chain complexes is regulated by specific subunits, which allow for adaptation to environmental changes. We found that upon shift of TAZ^KO^ cells to hypoxia (1% O~2~) for 24 hr, the expression of the tested hypoxia-specific isoforms of complex IV subunits (COX4-2, COX7-1) of the respiratory chain was drastically reduced ([Figure 1](#fig1){ref-type="fig"}C). The expression of these genes is under control of the hypoxia-inducible transcription factor HIF1 ([@bib16], [@bib22]). To this end, we assessed expression of established target genes of HIF-1α, including phosphoinositide-dependent protein kinase-1 (Pdk1), Phd2, and glucose transporter type 1 (Glut1), and found that their expression was similarly dampened in the absence of TAZ ([Figure 1](#fig1){ref-type="fig"}C). In agreement with these findings, the amount of the HIF-1α protein was significantly reduced in TAZ^KO^ cells compared to wild-type, in which a maximal amount of HIF-1α was apparent after 24 hr of hypoxia ([Figure 1](#fig1){ref-type="fig"}D). The phenotype of reduced HIF-1α level in hypoxia could be rescued in TAZ^KO^ Rescue cells, in which the mutations in the TAZ^KO^ were corrected through a second CRISPR-mediated homology repair (HR) event ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}B). The TAZ^KO^ cells displayed decreased expression of a luciferase-reporter gene under the control of an HIF-1-activated promoter, supporting the functional relevance of the observed reduced HIF-1α levels ([Figure 1](#fig1){ref-type="fig"}F).Figure 1Deficient Cardiolipin Remodeling Causes Blunted HIF-1α Response to Hypoxia(A) Total amounts of cardiolipin and monolysocardiolipin in wild-type (WT) and TAZ^KO^ MEF cells analyzed by mass spectrometry. Means ± SEMs, n = 4 per genotype. ^∗∗^p \< 0.01.(B) Cell count of WT and TAZ^KO^ MEF cells cultivated in galactose-containing media. Means ± SEMs, n = 4, ^∗^p \< 0.0001.(C) Analysis of gene expression of cytochrome *c* oxidase subunits (left) and canonical HIF-1α target genes (right) in total mRNA isolated from WT and TAZ^KO^ MEF cells subjected to normoxia and hypoxia for 24 hr by qPCR. Means ± SEMs, n = 3, ^∗^p \< 0.0294, ^∗∗^p \< 0.0001. ns, non-significant.(D) Analysis of steady-state protein levels in whole-cell extracts of WT and TAZ^KO^ MEF cells after exposing to normoxia or hypoxia for the indicated time points by western blotting with antibodies against indicated proteins (left). Quantification of a signal ratio of HIF-1α/β-actin after 24 hr of hypoxia with WT normoxia set to 1 (right). Means ± SEMs, n = 3, ^∗^p \< 0.04.(E) Analysis of HIF-1α steady-state levels under hypoxia and normoxia in WT, TAZ^KO^, and TAZ^KO^ Rescue MEF cells. Whole-cell lysates were analyzed by western blotting using antibodies against HIF-1α and β-tubulin.(F) HIF-1α activity measurement using luciferase reporter assay, as described in the [STAR Methods](#sec3){ref-type="sec"} for indicated time points under normoxia or hypoxia. Means ± SEMs, n = 3, ^∗^p \< 0.0001. ns, non-significant.(G) Steady-state protein levels analysis of whole-cell lysate from WT and TAZ^KO^ MEF cells after treatment with 2 mM DMOG or 50 μM CoCl~2~ for 24 hr by western blotting with antibodies against indicated proteins. n = 3.(H) Luciferase-reporter activity under control of an HIF-1α promoter as described in the [STAR Methods](#sec3){ref-type="sec"} after administration of 2 mM DMOG or 50 μM CoCl~2~ for 24 hr. Means ± SEMs, n = 3, ^∗^p \< 0.0005, ^∗∗^p \< 0.005.(I) Western blot analysis of HIF-1αsteady-state levels in cells treated with 25 μM of proteasomal inhibitor MG132 under normoxia and hypoxia for 8 hr. Antibodies against GAPDH and ACTB were used as a control.(J) Determination of HIF-1α degradation kinetics in WT and TAZ^KO^ MEF cells using cycloheximide chase for the indicated time points after 24 hr of hypoxia exposure. Quantitation of HIF-1α protein levels compared to β-tubulin in WT and TAZ^KO^ MEF cells. Means ± SEMs, n = 3.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

HIF-1α is a central regulator of a global metabolic transcription program and is therefore tightly regulated at the posttranslational level in the presence of molecular oxygen. HIF-1α is a short-lived protein, which is hydroxylated by PHDs and subsequently degraded through the ubiquitin/proteasome pathway. Accordingly, PHD inhibitors (dimethyloxaloylglycine \[DMOG\] and CoCl~2~) cause stabilization of HIF-1α even under normoxic conditions ([@bib23], [@bib34]). To address whether the reduced levels of HIF-1α in the absence of tafazzin were due to increased turnover, we treated TAZ^KO^ cells with PHD inhibitors CoCl~2~ and DMOG and the proteasome inhibitor MG132. While these treatments robustly increased the levels of HIF-1α in wild-type (WT) cells, HIF-1α levels were significantly lower in TAZ^KO^ cells ([Figures 1](#fig1){ref-type="fig"}G and 1I). Similarly, transcriptional activation, measured by HIF-1-driven luciferase activity levels, did not recover to WT levels in CoCl~2~- and DMOG-treated TAZ^KO^ cells ([Figure 1](#fig1){ref-type="fig"}H). Accordingly, the kinetics of HIF-1α turnover were similar in TAZ^KO^ and WT cells ([Figures 1](#fig1){ref-type="fig"}J and [S1](#mmc1){ref-type="supplementary-material"}G). Thus, the decreased HIF-1α levels in TAZ^KO^ cells were not caused by a failure to increase protein stability under hypoxia.

Cellular Gene Expression Is Altered in the Absence of Tafazzin {#sec2.2}
--------------------------------------------------------------

Because the reduced levels of HIF-1α in the absence of TAZ were obviously not linked to the established posttranslational regulatory process, we addressed whether a loss of TAZ affected the transcription of HIF-1α. For this, we analyzed HIF-1α mRNA levels in WT and TAZ^KO^ cells under normoxia and hypoxia. These qPCR analyses showed that in WT cells, expression of HIF-1α increased during hypoxia kinetically. However, this increase was not observed in the absence of TAZ, and mRNA levels remained at a basal expression rate ([Figure 2](#fig2){ref-type="fig"}A).Figure 2Differential Gene Expression Profiling Using RNA-Seq Reveals Depressed HIF-1α Transcriptional Regulation in TAZ^KO^ Cells(A) qPCR analysis of HIF-1α gene expression from total mRNA isolated at indicated time points from WT and TAZ^KO^ MEF cells under hypoxia and normoxia. Means ± SEMs, n = 3.(B) The volcano plot of log2 fold change versus −log10 p values shows induction of genes upon hypoxia in TAZ^KO^ MEF cells (right) in comparison with WT (left). Genes marked in green are statistically significant, with adjusted p ≤ 0.05 and log2 fold change of 1.0.(C) A heatmap showing the gene expression profile of selected HIF-1α target genes. The samples (mean of all replicates in each group) and genes are clustered with hierarchical clustering using Pearson correlation with average linkage. The expression levels are normalized using variance-stabilizing transformation and then centered and scaled row-wise indicated by the color scale from blue to red (representing low expression to high expression).(D) Heatmap showing the most significant pathways that are enriched in TAZ^KO^ cells compared to WT cells under hypoxia. The color bar represents −log10~e~ p values of the pathways, where darker color represents more significant pathways.See also [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}.

Using an unbiased alternative approach, we performed RNA sequencing (RNA-seq) analyses from WT and TAZ^KO^ cells grown under hypoxia and normoxia. In WT cells, the gene expression profile changed significantly upon the shift to oxygen-limiting conditions. This response was drastically dampened in TAZ^KO^ cells ([Figure 2](#fig2){ref-type="fig"}B; [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}). A strong reduction in hypoxia response was observed in particular for HIF-1α ([Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}) and its target genes ([Figure 2](#fig2){ref-type="fig"}C). Based on these data, we analyzed subunit swapping of normoxia-specific respiratory chain subunits (RCF1B and COX4-1) to hypoxia-specific isoforms (RCF1A and COX4-2). In agreement with the transcriptome data, the protein amounts of hypoxia-specific subunits were reduced in TAZ^KO^ ([Figure S2](#mmc1){ref-type="supplementary-material"}A). The TAZ-dependent changes in expression pattern extended beyond HIF-1α−induced genes. Several signaling and metabolic pathways, including nuclear factor κB (NF-κB) pathway targets, were significantly dampened in the absence of tafazzin ([Figure 2](#fig2){ref-type="fig"}D). The transcriptome data also revealed a selective reduction in TAZ expression in WT cells under hypoxic conditions, while other enzymes involved in cardiolipin biosynthesis were not decreased ([Table S1](#mmc2){ref-type="supplementary-material"}). We confirmed this finding by qPCR ([Figure S2](#mmc1){ref-type="supplementary-material"}B). In agreement with this, lipidome analyses of WT cells revealed an increased amount of MLCL under hypoxia ([Figures 1](#fig1){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}C). A hypoxia-dependent increase in MLCL levels was not observed in TAZ^KO^ cells; however, cardiolipin was significantly reduced under these conditions. Likewise, lipid profiles of WT and TAZ^KO^ cells under hypoxic conditions were significantly changed ([Figures S2](#mmc1){ref-type="supplementary-material"}C--S2E). Moreover, ceramide levels, which have been implicated in mitochondrial stress response signaling ([@bib24]), increased in hypoxia but remained similar between WT and TAZ^KO^ ([Figure S2](#mmc1){ref-type="supplementary-material"}E). We concluded that loss of tafazzin leads to alterations in gene expression and dampened transcription of HIF-1α. In addition, under conditions of limited oxygen supply, cells appear to increase the level of MLCL by reduced expression of TAZ.

NF-κB Activation Is Compromised when Cardiolipin Remodeling Is Affected {#sec2.3}
-----------------------------------------------------------------------

The expression of HIF-1α is under control of the transcription factor NF-κB ([@bib41]). The RNA-seq data indicated drastic changes in NF-κB-dependent gene expression ([Figure 2](#fig2){ref-type="fig"}D). To this end, we assessed whether NF-κB signaling was compromised in TAZ^KO^ cells and analyzed NF-κB activity with a reporter gene assay. While luciferase under control of a promoter with an NF-κB-binding element was \>2-fold induced in WT cells in hypoxia, this activation did not occur in TAZ^KO^ cells ([Figure 3](#fig3){ref-type="fig"}A). Because NF-κB translocates from the cytoplasm to the nucleus upon activation, we monitored the cellular distribution of NF-κB in normoxia and hypoxia. NF-κB efficiently and specifically accumulated in the nucleus under hypoxic conditions in WT cells. In contrast, in TAZ^KO^ cells nuclear translocation did not occur, which is indicative of inefficient NF-κB activation ([Figure 3](#fig3){ref-type="fig"}B).Figure 3NF-κB-Mediated Gene Induction of HIF-1α Is Required for Adequate Response to Hypoxia(A) NF-κB activity measurement using luciferase reporter assay as described in the [STAR Methods](#sec3){ref-type="sec"} for 24 hr under normoxia or hypoxia. Means ± SEMs, n = 4, ^∗^p \< 0.0177; ns, non-significant.(B) Determination of NF-κB nuclear translocation under normoxia and hypoxia for 24 hr in WT and TAZ^KO^ MEF cells by immunostaining the cells with antibodies against NF-κB-p65 (green) and DAPI (blue). Bars, 15 μm. N, normoxia; H, hypoxia. Quantification of cells with nuclear NF-κB to cytoplasmic localization as described in the [STAR Methods](#sec3){ref-type="sec"}. Means ± SEMs, n = 3, ^∗∗^p \< 0.05.(C) Flow cytometry detection of changes in mitochondrial ROS levels by staining WT and TAZ^KO^ MEF with MitoSOX Red after exposure to hypoxia or normoxia for 24 hr. Means ± SEMs, n = 4, ^∗^p \< 0.05.(D) Quantitation of ROS production over time in isolated mitochondria from WT and TAZ^KO^ MEF cells exposed to hypoxia or normoxia for 24 hr using the ROS-specific fluorescence-based sensor 2\',7\'-dichlorodihydrofluorescein diacetate (H~2~DCFDA). Means ± SEMs, n = 3.(E) Western blot analysis of HIF-1α protein levels under hypoxia in the presence and absence of 0.5 and 1 mM NAC using anti-β-tubulin antibody as a control.(F) Determination of HIF-1α protein levels in comparison to β-tubulin under hypoxia in the presence and absence of 450 μM paraquat in WT and TAZ^KO^ MEFs.(G) Analysis of NF-κB nuclear translocation in WT and TAZ^KO^ MEFs under hypoxia and normoxia in the presence and absence of 450 μM paraquat. NF-κB was detected by immunostaining with antibodies against NF-κB -p65 (green) and DAPI (blue). Bars, 15 μm. N, normoxia; H, hypoxia. The graph on the right shows quantification of cells with NF-κB to cytoplasmic localization that has been done as described in the [STAR Methods](#sec3){ref-type="sec"}. Means ± SEMs, n = 3, ^∗^p \< 0.05.(H) qPCR analysis of HIF-1α gene expression from total mRNA isolated from WT and TAZ^KO^ MEF cells under hypoxia and normoxia in the presence and absence of 450 μM paraquat. Means ± SEMs, n = 3.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Reactive oxygen species (ROS) are among the key stimuli that activate NF-κB at the plasma membrane in T cells and epithelial cells ([@bib37]). Therefore, we assessed superoxide anion production in MEF cells in normoxia and hypoxia. First, we measured superoxide anion production by flow cytometry in WT and TAZ^KO^ cells. In WT cells, the production of superoxide anion was drastically increased in hypoxia. In contrast, this hypoxia-specific increase in superoxide levels was diminished in TAZ^KO^ cells by approximately 50% ([Figure 3](#fig3){ref-type="fig"}C). Second, we measured the kinetics of ROS production in purified mitochondria from WT and TAZ^KO^ cells grown in hypoxia or normoxia. Mitochondria from normoxic TAZ^KO^ cells displayed increased ROS production compared to WT cells. The production of ROS in WT mitochondria increased drastically when cells were grown under hypoxic conditions. However, the production of mitochondrial ROS increased significantly less in the TAZ^KO^ sample than in the WT ([Figure 3](#fig3){ref-type="fig"}D). The reduction in ROS emission in TAZ^KO^ mitochondria is in line with a reduction in the mitochondrial inner membrane potential ([Figure S3](#mmc1){ref-type="supplementary-material"}A). In summary, in hypoxia TAZ deficiency leads to decreased mitochondrial ROS production compared to WT.

To assess the role of ROS signals in the induction of HIF-1α, we treated cells with ROS-quenching *N*-acetyl cysteine (NAC). NAC treatment blocked HIF-1α activation under hypoxic growth conditions ([Figure 3](#fig3){ref-type="fig"}E). Similar results were obtained using the mitochondria-targeted ROS scavenger MitoTEMPO ([Figure S3](#mmc1){ref-type="supplementary-material"}B). We reasoned that if defective NF-κB activation in TAZ^KO^ cells was linked to reduced ROS production in mitochondria, then we should be able to complement HIF-1α expression by increasing mitochondrial ROS production chemically. To this end, TAZ^KO^ cells were treated with paraquat to increase ROS production by the respiratory chain ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D). The response of TAZ^KO^ to paraquat appeared quantitatively less than in WT MEF cells. This is likely due to alterations in the respiratory complexes upon cardiolipin deficiency ([Figure S1](#mmc1){ref-type="supplementary-material"}C). In the paraquat-treated cells, HIF-1α reached WT levels under hypoxic conditions ([Figure 3](#fig3){ref-type="fig"}F). Moreover, paraquat treatment also complemented the nuclear translocation phenotype of NF-κB in TAZ^KO^ cells ([Figure 3](#fig3){ref-type="fig"}G) and the decrease in HIF-1α mRNA levels in TAZ^KO^ cells ([Figure 3](#fig3){ref-type="fig"}H). In addition, paraqaut treatment increased the activity of NF-κB in TAZ^KO^ cells upon hypoxia ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Similarly, antimycin A and rotenone treatment to induce ROS through complex III and complex I corrected NF-κB nuclear translocation in TAZ^KO^ cells ([Figure S4](#mmc1){ref-type="supplementary-material"}A). These analyses demonstrated that mitochondrial ROS production needs to reach a critical threshold to activate NF-κB signaling in hypoxia and thus to trigger a physiologically adequate response of HIF-1α.

Blunted HIF-1α Signaling Causes Increased Susceptibility to Heart Failure in Barth Syndrome Mouse Model {#sec2.4}
-------------------------------------------------------------------------------------------------------

To this end, we addressed whether HIF-1 signaling was similarly affected in disease models of Barth syndrome using patient induced pluripotent stem cell (iPSC)-derived cardiomyocytes (TAZ 10) ([@bib15]). HIF-1α stabilization displayed significantly faster kinetics in these cells compared to MEF cells. Moreover, in TAZ 10 cardiomyocytes, a significant reduction in HIF-1α protein level was apparent under hypoxic conditions, which went along with a blunted induction of its target genes ([Figures 4](#fig4){ref-type="fig"}A and 4B). As expected, inhibitors of HIF-1α hydroxylation did not rescue HIF-1α protein levels, excluding that increased HIF-1α turnover was the cause for reduced protein levels in Barth syndrome (BTHS) cardiomyocytes ([Figure 4](#fig4){ref-type="fig"}C). In agreement with this, HIF-1α had a 7-min half-life in BTHS and control cardiomyocytes. However, under hypoxia, HIF-1α gene induction was affected in TAZ 10 cardiomyocytes ([Figure 4](#fig4){ref-type="fig"}D). Reporter gene assays of NF-κB activity in TAZ 10 cardiomyocytes revealed decreased transcriptional reporter activation ([Figure 4](#fig4){ref-type="fig"}E). Accordingly, also in patient-derived cardiomyocytes, HIF-1α gene induction in hypoxia requires the activation of NF-κB signaling.Figure 4Decreased HIF-1α Signaling in Barth Syndrome Patient iPS-CM and shTAZ Mice(A) Analysis of HIF-1α protein stability in control versus TAZ 10 iPS-CM after exposure to normoxia or hypoxia for the indicated time points.(B) qPCR analysis of the HIF-1α target *Pdk1* in total mRNA isolated from control versus TAZ 10 iPS-CM subjected to normoxia and hypoxia for 8 hr by qPCR. Means ± SEMs, n = 3, ^∗^p \< 0.01.(C) Determination of HIF-1α protein stability in whole-cell lysates from control versus TAZ 10 iPS-CM upon administration of 2 mM DMOG or 50 μM CoCl~2~ for 24 hr by SDS-PAGE followed by western blotting with antibodies against HIF-1α and β-tubulin. n = 3.(D) qPCR analysis of HIF-1α gene expression from total mRNA isolated at indicated time points from control versus TAZ 10 iPS-CM under hypoxia and normoxia conditions. Means ± SEMs, n = 3, ^∗∗^p \< 0.03.(E) Quantification of NF-κB-p65 activation in nuclear extracts isolated from control and TAZ 10 iPS-CM after hypoxia and normoxia for the indicated time points using ELISA-based NF-κB p65 transcription factor assay kit. Means ± SEMs, n = 3, ^∗^p \< 0.05; ns, non-significant.(F) Representative picture of mouse hearts dissected from WT and shTAZ after 4 weeks of sham and TAC surgery.(G) Determination of HIF-1α protein levels in tissue lysates from hearts of WT and shTAZ mice after 4 weeks of sham and TAC surgery.(H) Quantification of the heart weight-to-body weight ratio in WT and shTAZ before (pre) and after 2 weeks (2W) or 4 weeks (4W) of sham and TAC surgery. Means ± SEMs, n = 8 in WT, n = 12 in shTAZ, ^∗∗^ unpaired t test: p \< 0.05, ^∗^ and ^∗∗∗^ paired t tests: p \< 0.05.(I) Quantification of the percentage of fractional area shortening in WT and shTAZ before (pre) and after 2 weeks (2W) or 4 weeks (4W) of sham and TAC surgery. Means ± SEMs, n = 8 in WT, n = 12 in shTAZ, ^∗∗^ unpaired t test: p \< 0.05, ^∗^ and ^∗∗∗^ paired t tests: p \< 0.05.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

HIF-1α plays key roles in signaling pathways in the heart muscle in response to stress ([@bib5]). We therefore analyzed the response of cardiac tissue to pressure overload induced by transversal aortic constriction (TAC) in the BTHS mouse model (shTAZ). Here, we found a drastic morphological difference between control and BTHS mice in response to pressure overload ([Figure 4](#fig4){ref-type="fig"}F). While HIF-1α levels increased in control mouse hearts, this effect was severely reduced in shTAZ mice ([Figure 4](#fig4){ref-type="fig"}G). The heart responds to TAC surgery with hypertrophy in an effort to compensate the increased afterload. Long-term exposure to mechanical stress results in decompensation and heart failure. Failing HIF-1α signaling in shTAZ mouse hearts causes significant progression into decompensated heart failure upon TAC surgery. The hearts of shTAZ mice show a significant augmented hypertrophy response ([Figures 4](#fig4){ref-type="fig"}H, [S4](#mmc1){ref-type="supplementary-material"}B, and S4C), while cardiac function, as determined by fractional shortening and ejection fraction, strongly decreased ([Figures 4](#fig4){ref-type="fig"}I and [S4](#mmc1){ref-type="supplementary-material"}D). Moreover, the hearts of shTAZ mice displayed an increase in *Bnp* (brain natriuretic peptide) expression, which is indicative of transition to heart failure ([Figure S4](#mmc1){ref-type="supplementary-material"}E). These data demonstrate that in the absence of tafazzin, mice hearts lost the capacity to adapt to pressure overload challenges and that HIF-1α function is compromised under these conditions. However, considering the broad impact of loss of tafazzin on metabolism and signaling processes, the observed reduced adaptive capacity of the heart may be influenced by other processes in addition to the reduction in HIF-1α functionality.

Conclusions {#sec2.5}
-----------

Our results reveal a link between mitochondrial cardiolipin remodeling and HIF-1 signaling. Previous work suggested a connection between mitochondria-derived ROS and HIF-1α stabilization. However, the suggested mechanistic concept predicted an effect of ROS on PHD enzymatic function and thus conveyed a posttranslational effect on HIF-1α ([@bib8], [@bib9]). Here, we demonstrate that ROS in fact trigger a transcriptional response that is communicated from mitochondria to the nucleus through NF-κB. Such a mechanism of ROS-induced activation of NF-κB phenocopies the activation cascade for NF-κB in inflammatory responses and tumor tissue ([@bib37], [@bib39]). While our observations provide principal mechanistic insight into how mitochondrial retrograde signaling in hypoxia occurs, we also demonstrate that this pathway is physiologically relevant. In BTHS models, HIF-1α activation is compromised because mitochondrial ROS levels drop beyond the activation threshold for NF-κB. At the same time, we recognize regulatory feedback under conditions of hypoxic growth at which TAZ expression is downregulated to increase MLCL in mitochondria. These findings provide a mechanistic framework for mitochondrial retrograde signaling and demonstrate that in BTHS signaling defects affect the ability of the heart muscle to cope with functional challenges.

STAR★Methods {#sec3}
============

Key Resources Table {#sec3.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Mouse anti-HIF-1αNovus BiologicalsCat\#NB100-479; RRID: [AB_10000633](nif-antibody:AB_10000633){#interref75}Human anti-HIF-1αBD BiosciencesCat\#610959; RRID: [AB_398272](nif-antibody:AB_398272){#interref80}anti-PDK1Stressgen BiotechnologiesCat\#KAPPK112; RRID: [AB_2039453](nif-antibody:AB_2039453){#interref85}anti-GLUT1Novus BiologicalsCat\#NB300-666; RRID: [AB_10000485](nif-antibody:AB_10000485){#interref90}anti-PHD3Novus BiologicalsCat\#NB100-303; RRID: [AB_10003302](nif-antibody:AB_10003302){#interref95}anti-GAPDHAbcamCat\#ab75834; RRID: [AB_1310254](nif-antibody:AB_1310254){#interref100}Anti-β-actin (ACTB)SigmaCat\#A5441; RRID: [AB_476744](nif-antibody:AB_476744){#interref105}anti-β-tubulin (TUBB)AbcamCat\#ab6064Anti-COX4-2ProteintechCat\#11463-1-AP; RRID: [AB_2085287](nif-antibody:AB_2085287){#interref110}anti-COX4-1SelfmadePR-1522anti-RCF1ASelfmadePR-3976anti-RCF1BSelfmadePR-3977anti-TIM23SelfmadePR-1526anti-ATP5BSelfmadePR-4826anti-VDAC3SelfmadePR-1514anti-Tom70SelfmadePR-3280anti-MnSODNovus BiologicalsCat\#NB100-1992; RRID: [AB_535862](nif-antibody:AB_535862){#interref115}Anti-NF-kappaB p65Cell SignalingCat\#8242S; RRID: [AB_10859369](nif-antibody:AB_10859369){#interref120}anti-TafazzinAbcamCat\#ab93362; RRID: [AB_10562289](nif-antibody:AB_10562289){#interref125}Secondary antibody Goat anti-rabbit IgG-488 Alexa fluorThermo scientificCat\#A-11034; RRID: [AB_2576217](nif-antibody:AB_2576217){#interref130}Goat anti-mouse HRP-coupled secondary antibodyJackson ImmunoResearchCat\#115-035-146; RRID: [AB_2307392](nif-antibody:AB_2307392){#interref135}Goat anti-rabbit HRP-coupled secondary antibodyJackson ImmunoResearchCat\#115-035-144**Chemicals, Peptides, and Recombinant Proteins**GeneJuiceMerckCat\#70967-3Lipofectamine 2000ThermoFisher ScientificCat\#11668019TrizolThermoFisher ScientificCat\#15596026DAPI FluoroshieldSigma-AldrichCat\#F6057CM-H~2~DCFDAThermoFisherCat\#C6827MitoSOX RedThermoFisherCat\#M36008TMRMThermoFisherCat\#T668ParaquatSigmaCat\#36541DMOGENZOCat\#BML-EI 247-0050CoCl~2~FlukaCat\#60820N-acetylcysteine (NAC)SigmaCat\#A7250Antimycine ASigmaCat\#A8674RotenoneSigmaCat\#R8875MG132Cayman via BertiPharmaCat\#10012628MitotempoSigmaCat\#C1988DAPI FluoroshieldSigma-AldrichCat\#F6057CM-H~2~DCFDAThermoFisherCat\#C6827**Critical Commercial Assays**QuikChange Site-Directed Mutagenesis KitAgilentCat\#210515KOD Hot Start DNA PolymeraseMerckCat\#71086-3First Strand cDNA Synthesis kitThermoFisher ScientificCat\#K1612SensiMix SYBR Low-Rox One Step kitBiolineCat\#QT625-05Dual-luciferase reporter assay systemPromegaCat\#E1910Nuclear Extraction KitAbcamCat\# ab113474NF-κB p65 transcription factor assay kitAbcamCat\# ab207221**Deposited Data**RNA sequencing dataGene Expression OmnibusAcc\# GSE119775**Experimental Models: Cell Lines**Mouse: MEF cellsATCCN/AMouse: MEF cells TAZ^KO^This paperN/AMouse: MEF cells TAZ^KO^ RescueThis paperN/AHuman: iPSC WTD2.3[@bib15]N/AHuman: iPSC TAZ 10.3[@bib15]N/A**Experimental Models: Organisms/Strains**Mouse: ROSA26H1/tetO-shRNA:TAZ[@bib1]MGI:[4887237](mgi:4887237){#intref0010}**Oligonucleotides**gRNA1 sequence: TAGGCCCATGACGACGCTGCThis paperN/AgRNA2 sequence: TGTGAAGTGGCCATTCCCCGThis paperN/AssODN Repair template: GGCGGGGCCGGAGCCGGAGGAGAT\
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Contact for Reagent and Resource Sharing {#sec3.2}
----------------------------------------

Further information and requests for reagents may be directed to, and will be fulfilled by the corresponding author Peter Rehling (<Peter.Rehling@medizin.uni-goettingen.de>).

Experimental model and subject details {#sec3.3}
--------------------------------------

### Mice {#sec3.3.1}

Maintenance of all mice and the study on them were performed according to the guidelines from the German Animal Welfare Act and approved by the Landesamt für Verbraucherschutz und Lebensmittelsicherheit, Niedersachsen, Germany (AZ: 33.9-42502-04-15/1991). Administration of doxycycline (625 mg/kg) was done as part of the standard rodent chow to WT C57BL/6J mice and transgenic (ROSA26H1/tetO-shRNA:TAZ) animals ([@bib1], [@bib38]). Female mice were treated with doxycycline 1 week before mating and doxycycline was withdrawn during mating to avoid male infertility. Once copulatory plugs were detected Doxycycline treatment was resumed and the pups were continuously treated until 2 months of age. The genotype of the pups was assessed by PCR, as described previously ([@bib1]). For Transverse aortic constriction (TAC) female mice of an age between 8 and 12 weeks were used for experiments. TAC was performed by surgical placement of a suture around the transverse aorta sized to a 26G needle, as described previously ([@bib20]). Mice were subjected either to TAC or a sham operation. The appropriate painkillers were administered subcutaneously pre and post surgeries. Mice were euthanized at 2 or 4 weeks after surgery for tissue harvest and analysis. The echocardiography was performed prior to surgery as well at 2 weeks or 4 weeks after intervention prior to sacrificing the animals. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. For transthoracic echocardiography, Vevo2100 (VisualSonics, Toronto, Canada) system with a 30-MHz center frequency transducer was used. In short, animals were anesthetized with 3% isoflurane and temperature-, respiration, and ECG controlled anesthesia was maintained with 1.5% isoflurane. Two dimensional cine loops with frame rates of \> 200 frames/s of a long-axis view and a short-axis view at mid-level of the papillary muscles as well as M-mode loops of the short-axis view were recorded. Thicknesses of the septum, the posterior myocardial wall, the inner diameter of the left ventricle (LVED), and the area of the left ventricular cavity (area) were measured in systole (s) and diastole (d) from the short-axis view according to standard procedures ([@bib11]). Maximal left ventricular length (L) was measured from the long-axis view. Systolic and diastolic left ventricular volumes were calculated using the area**--**length method, and the ejection fraction (EF) was calculated out of the volumes. Measurements were obtained by an examiner blinded to the genotype of the animals.

### Cell lines and cultivation {#sec3.3.2}

SV40-large T immortalized and H-ras transformed MEF cells were cultured in DMEM, supplemented with 10% \[v/v\] fetal bovine serum (FBS) (GIBCO, Invitrogen) at 37°C under a 5% CO~2~ humidified atmosphere. Lipofectamine 2000 (Thermo Scientific) was used for transfections, which were performed according to manufacturer's recommendations. Briefly, approximately 300,000 cells/25 cm^2^ were transfected using 4 μL of transfection reagent and 1 μg of DNA TAZ^KO^ cell line was generated using the CRISPR/Cas9 technology as previously described ([@bib35]). Briefly, oligonucleotides 5′-TAGGCCCATGACGACGCTGC-3′ and 5′-GCAGCGTCGTCATGGGCCTA-3′ containing the guide sequences were annealed and ligated into the pX330 vector. WT MEFs cells were co-transfected with pX330 and with the pEGFP-N1 plasmid. After three days, single cells expressing GFP were sorted by flow cytometry into 96 well plates. After colony expansion single colonies were screened by sequencing. TAZ^KO^ Rescue was generated through CRISPR/Cas9 mediated repair of the mutant alleles. The guide RNA sequence used for this purpose is 5′-TGTGAAGTGGCCATTCCCCG-3′. The guides were cloned into pX330-GFP (GFP expression through an independent CMV promoter). TAZ^KO^ cells were co-transfected with pX330-GFP and ssODN repair template, 5′-GGCGGGGCCGGAGCCGGAGGAGATGCCCCTCCATGTGAAGTGGCCCTTTCCTGCAGTTCCTAGACTCACCTGGACTCTAGCCAGCAGCGTCGTCATGGGCCTAGTTGGCACCTACAGCTGCTTCTGGACCAGTGAGTGGCAAAAGGCCAA-3′. The cells were screened as mentioned above for the correction.

For studying cell proliferation under different growth conditions, 1x10^5^ WT and TAZ^KO^ MEF cells were initially plated in media containing either glucose (9 g/L) or galactose (0.9 g/L). The cells were counted after every 24 hours using a haemocytometer.

### Control and patient-specific iPS-CM {#sec3.3.3}

Generation of the patient-specific iPS-CM (control and TAZ 10) was done as described previously ([@bib15], [@bib26]). The control iPS-CM line was derived from a healthy individual, whereas TAZ 10 was generated from a BTHS patient carrying the mutation c.590 G \> T in the TAZ gene ([@bib14]). All hiPSC lines were expanded as adherent cultures in feeder- dependent cultures on Geltrex-coated cell culture dishes in the presence of chemically defined E8 Essential Medium, (Life Technologies). Differentiation of hiPSC to cardiomyocytes was performed over a period of 30 days, based on small molecules-mediated canonical Wnt pathway modulation as reported previously. Enrichment for cardiomyocytes was performed by adding 4 mM lactate in substitution of glucose for 6 days between days 20 and 30 ([@bib40]). Cultures of iPS-CMs were then enzymatically dissociated into single cells using 0.25% trypin-EDTA (Life technologies) and further plating and culturing CMs was done in RPMI 1640 (HEPES/GlutaMax) (Life technologies) medium supplemented with B27 and insulin (Life technologies).

Method Details {#sec3.4}
--------------

### Cell compound treatments {#sec3.4.1}

For inducing hypoxia, the MEF cells or iPS-CM were incubated under defined hypoxic conditions (1% O~2~), an *in vivo* hypoxia workstation (Baker Ruskinn, The Baker Company, Bridgend, South Wales, United Kingdom). For normoxia, the cells were maintained in a regular cell culture incubator (with 20% O~2~). For inhibiting PHD activity under normoxic condition the cells were treated either with 50 μM CoCl~2~ or 2 mM DMOG for 24 hours. MEF cells were treated with 450 μM Paraquat, 20 hours after hypoxia induction. The treatment was continued for additional 4 hours under hypoxic condition. Other oxidants such as Antimycin A and Rotenone were used at 0.2 mM each for similar durations. The cells were then processed for cell lysate preparation or immunostaining. For quenching ROS levels, N-acetylcysteine (NAC) (1 M prepared in culture medium, pH adjusted to 7.2) was added to culture medium at a final concentration of 0.5 or 1 mM for 24 hours during hypoxia. Similarly, MitoTempo was used at 0.05 mM for 24 hours during hypoxia. To block proteasomal activity of HIF-1α the cells were treated with a final concentration of 25 μM MG132, added to culture medium of the cells for 8 hours under hypoxia or normoxia. For determining the half-life of endogenous HIF-1α, 50 μM of cycloheximide (CHX) was added to the cells inside the hypoxia workstation after 24 hours of hypoxia treatment. The cells were then taken out after 1, 2, 4, 7 and 10 mins of CHX treatment for cell lysate preparation.

### Luciferase reporter gene assay {#sec3.4.2}

For determining HIF-1 activity, cells were co-transfected with 100 ng of the HIF-dependent *Firefly* luciferase reporter gene construct pH3SVL as described previously ([@bib43]) and 5 ng of the constitutively active pRLSV40 *Renilla* luciferase reporter plasmid (Promega, Madison, WI, USA) to control for differences in transfection efficiency. Alternatively, for NFκB activity analysis the cells were co-transfected with 100 ng of the NFκB-dependent firefly luciferase reporter gene construct, pNF-κB-Luc (Clontech) and 5 ng of pRLSV40 *Renilla* luciferase reporter plasmid (Promega, Madison, WI, USA) to control for differences in transfection efficiency. At 6 hours post-transfection, cells were equally distributed and exposed to 20% or 1% O~2~ for another 24 hours. After washing with PBS and carrying out cell lysis using passive cell lysis buffer (Promega), Firefly and *Renilla* luciferase reporter activities were determined using the dual-luciferase reporter assay system according to the manufacturer's instructions (Promega) using a microplate luminometer (Berthold, Regensdorf, Switzerland).

### Immunofluorescence analyses {#sec3.4.3}

Immunofluorescence staining was performed using standard protocols ([@bib10]). Cells grown on coverslips were kept in hypoxia or normoxia for 24 hours and were fixed in 4% paraformaldehyde (Roth). Cells were permeabilized with 0.2% Triton X-100 (Roth). After washing with PBS, non-specific binding sites were blocked with 1% BSA + 1% goat serum in PBS and stained with anti-NFκB-p65 rabbit monoclonal antibody (\#8242, Cell signaling, 1:400) for one hour. After washing coverslips were further incubated for 2 hours with the secondary antibody Goat anti-rabbit IgG-488 Alexa fluor (A-11034 Thermo scientific). After final washing, cells were mounted in histology mounting medium containing DAPI (Fluoroshield; Sigma-Aldrich, F6057). Fluorescence micrographs were captured using a DeltaVision Spectris fluorescence microscope (Applied Precision) at 60X magnification, equipped with a FITC (excitation 475/28, emission 523/36) and DAPI (excitation 390/18, emission 435/48) filter set. A series of 15-20 sections with 0.5-μm spacing along the Z axis were taken. Images were deconvoluted and projections were created from stacks by merging the individual slices using the softWoRx software (Applied Precision).

The imaging analysis was performed as follows, relying on self-written routines in MATLAB (The Mathworks, Inc., Natick, MA, USA). Nuclei were identified by DAPI staining. Each individual nucleus was identified using an automatic thresholding procedure that removed all signals close to background fluorescence, thereby maintaining only nuclei. The immunostaining intensity within the regions of interest representing the nuclei was then determined automatically, within the respective images. To obtain the fluorescence levels within the cytosol of the respective cells, each region of interest corresponding to a nucleus was dilated using an appropriate scaling factor (which was identical for all cells), thus obtaining a circular region of interest that bordered each nucleus. The signal intensity in this new region of interest was then automatically measured, and was compared to the signal within the respective nucleus.

### ROS measurement with H~2~DCFDA {#sec3.4.4}

CM-H~2~DCFDA (5-(and-6)-chloromethyl-2′,7'-dichlorodihydro fluorescein diacetate, acetyl ester) was used as a detector of ROS as described previously ([@bib15]). The mitochondria isolated from MEFs were resuspended in 10 μM H~2~DCFDA in assay buffer (20 mM Tris**-**HCl, 150 mM NaCl, 1% Triton X-100, pH 7.4). The changes in fluorescence at an excitation wavelength of 498 nm and an emission wavelength of 525 nm were determined using a fluorescence spectrophotometer (Hitachi F-7000) for 700 s. For each sample of a given experiment, the measurement was performed in triplicate, and expressed as arbitrary fluorescence intensity units (AFU).

### Flow cytometry analyses {#sec3.4.5}

The BD-Canto flow cytometer (Becton Dickinson) was used for flow cytometry. Analyses were performed on 10,000 gated events and numeric data were processed using the FACS-Diva software. For estimation of mitochondrial membrane potential, TMRM was used at a concentration of 100 nM. Cells were stained with MitoSOX Red at a concentration of 3 μM for measuring mitochondrial superoxide anion production. In each case, 10^6^ cells were stained with the respective dyes after the indicated treatments using the vendor\`s protocols. For cells treated with hypoxia the entire staining procedure was carried out inside the hypoxia chamber under stable and controlled 1% O~2~ oxygen concentration. After fixation with 4% paraformaldehyde, the final steps were then carried out outside the workstation in normoxic conditions.

### NF-κB activity assay {#sec3.4.6}

A total of 1 × 10^7^ TAZ 10 iPS-CM cells were plated in 10 cm cell culture dishes a day prior to the experiment. The cells were then subjected to hypoxia for the indicated time points. While in hypoxia the cells were harvested using 0.25% Trypsin-EDTA and washed with 1X PBS inside the hypoxia chamber. They were then lysed using the Pre-extraction buffer provided in the Nuclear Extraction Kit (Abcam, Cat. No. ab113474). Post lysis, the following steps were carried outside the hypoxia chamber. The nuclear lysates were then processed for NF-κB p65 transcription factor assay kit (Abcam, Cat. No. ab207221) according to the vendor\'s protocol. The plate was read in the Centro LB960 Luminometer plate reader (Berthold technologies) and the values were expressed as Relative light units (RLU).

### Analysis of lipid profiles by mass spectrometry {#sec3.4.7}

WT and TAZ^KO^ MEF corresponding to 1.5-2.0 nmol of total lipid were subjected to acidic Bligh and Dyer lipid extractions ([@bib6]) except for CL and MLCL. Lipid standards were added prior to extractions, using a master mix containing phosphatidylcholine (13:0/13:0, 14:0/14:0, 20:0/20:0; 21:0/21:0, Avanti Polar Lipids), D6-cholesterol (Cambridge Isotope Laboratory), phosphatidylinositol (16:0/16:0, 17:0/20:4, Avanti Polar Lipids), phosphatidylethanolamine, phosphatidylglycerol and phosphatidylserine (each 14:1/14:1, 20:1/20:1, 22:1/22:1, semi-synthesized as described in ([@bib32]), sphingomyelin, ceramide and glucosylceramide (d18:1 with N-acylated 15:0, 17:0, 25:0 each, semi-synthesized as described ([@bib32]), phosphatidic acid (17:0/20:4, Avanti Polar), and lactosylceramide (d18:1 with N-acylated C12 fatty acid). Plasmalogens were quantified as described in ([@bib18]). Evaporated lipids were redissolved in 60 μl 10 mM ammonium acetate in methanol and analyzed on a QTRAP6500+ mass spectrometer (Sciex, Canada) with chip-based (HD-D ESI Chip, Advion Biosciences, USA) electrospray infusion and ionization via a Triversa Nanomate (Advion Biosciences, Ithaca, USA) as previously described ([@bib32]). Redissolved lipid extracts were diluted 1:10 in 96-well plates (Eppendorf twintec 96, Sigma) prior to measurement. Precursor and neutral loss scanning in positive ion mode was employed to measure glycerophospholipids as described ([@bib32]). Remaining samples were subjected to cholesterol determination as described ([@bib32]). Data evaluation was done using LipidView (Sciex, Canada) and a software developed in-house (ShinyLipids). For MS analysis of CL and MLCL, lipids were extracted by MTBE extraction as described in ([@bib28]). Lipid extracts were dried under a gentle nitrogen stream. Dried lipids were re-dissolved in 40% UPLC solvent B (90% 2-propanol/10% acetonitrile /0.1% formic acid/ 10 mM NH~4~HCO~2~) and transferred to silanized glass inserts (Phenomenex) using Hamilton syringes. The glass inserts were placed in Eppendorf tubes and centrifuged in an Eppendorf centrifuge at 9000 rpm for 1.5 minutes. Lipid samples were then subjected to UPLC-ESI-MS/MS analysis performed on an Ultimate^®^ 3000 LC system (Dionex, Thermo Fisher Scientific) coupled to a Q Exactive Hybrid Quadrupole-Orbitrap instrument (Thermo Scientific). For LC separations, a ACQITY UPLC CSH C18 1.7μm, 1.0 × 150 mm column (Waters) was used. The column oven temperature was set to 55°C, the temperature of the autosampler was set to 20°C. The flow rate used was 100 μL/min. The solvent composition used was as follows: 60% acetonitrile/40% H~2~O/0.1% formic acid/10 mM NH~4~HCO~2~ (solvent A), 90% 2-propanol/10% acetonitrile /0.1% formic acid/ 10 mM NH~4~HCO~2~ (solvent B). The starting solvent composition was 40% solvent B/60% solvent A. The conditions of the gradient were as follows: 3 min: 50% solvent B, 9 min: 54% solvent B, 9.1 min: 70% solvent B, 17-22 min: 90% solvent B and 22.5-30 min: 40% solvent B. The MS analyses were performed in the negative ion mode. The following ESI source parameters were used: sheath gas flow rate: 4 (a.u.), auxilliary gas flow rate: 0, sweep gas flow rate: 0, spray voltage: 4 kV, capillary temperature: 320°C, S-lens RF level: 50. Full-MS scans were recorded using the following parameters: FWHM peaks: 15 s, resolution: 140,000 (at m/z 200) AGC-target: 1e6, maximum IT: 200 ms, scan range: m/z 500-2000. Data evaluation was performed using MassMap.

### RNA analyses {#sec3.4.8}

#### RNA isolation and RT-qPCR {#sec3.4.8.1}

RNA was isolated from the cells or tissue samples using the TRIzol reagent (Invitrogen), according to the manufacturer's protocol. For cells subjected to hypoxia the TRIzol reagent was added while cells were inside the hypoxia workstation. The total RNA was reverse-transcribed into cDNA using M-MuLV Reverse Transcriptase (Thermo Scientific) and random hexamer primers. Quantitative real-time (qRT)-PCR was performed in triplicate, using the SensiMix SYBR Low-Rox One Step kit (Bioline, Cat. No. QT625-05), in a QuantStudio 6 flex cycler (Applied Biosystems). All primer sequences are available upon request.

#### RNaseq analyses {#sec3.4.8.2}

For processing of sequencing data, a customized in-house software pipeline was used. Illumina's bcl2fastq (v1.8.4) was used to convert the base calls in the per-cycle BCL files to the per-read FASTQ format from raw images. Along with base calling, adaptor trimming and demultiplexing were performed. Quality control of raw sequencing data is performed using FastQC (v 0.11.5). We then map the reads to the mouse transcriptome (Mus_musculus.GRCm38.86). Remaining unmapped reads were then mapped to the mouse genome (mm10). We used rna-STAR (version STAR_2.5.2b) for all the mapping. We allowed no mismatches for the reads \< 19b, one mismatch for reads between 20b to 39b, two mismatches for reads between 40b to 59b and so on. We mapped all the reads in the non-splice-junction-aware mode. All other parameters were used in default settings by rna-STAR. The number of aligned reads overlapping it exons for each gene is then counted with the intersection-non-empty mode using htseq-count script available with HTSeq package (version 0.9.1).

#### Differential Expression Analyses {#sec3.4.8.3}

To identify the differentially expressed genes, we first identify unwanted sources of variation (RUVs) and corrected them using RUVSeq (v. 1.8.0). We then used DESeq2 (v. 1.14.1) to perform the differential expression analysis. We then used the genes that were found significantly differentially expressed with base mean \> = 35, log2 fold change \< \> 0.20 and p-adjusted ≤ 0.05.

### Protein analyses {#sec3.4.9}

#### Blue native (BN)--PAGE and respiratory chain activity staining {#sec3.4.9.1}

Standard protocols for BN-PAGE were used as described previously ([@bib30]). Mitochondrial membranes, solubilized in 1% digitonin were subjected for BN-PAGE analysis on a 4%--14% polyacrylamide gradient gel as described ([@bib12]). Activity staining of native respiratory chain complexes was performed as described previously ([@bib44]). In brief, complex I activity was visualized in using 2.5 mg/ml nitrotetrazolium blue (NTB) and 0.1 mg/ml NADH, in 5 mM Tris, pH 7.4 at 37°C. Complex IV was visualized, using cytochrome *c* reduced with 15 mg/ml Na-dithionite, which was added to a concentration of 1 mg/ml to the staining solution containing 0.5 mg/ml diaminobenzidine in 50 mM KPi, pH 7.4.

#### Mitochondria isolation and western blotting {#sec3.4.9.2}

Isolation of mitochondria from the cells or cardiac tissues was performed as described in ([@bib25]). The tissue was first mechanically disrupted and then homogenized in a potter in homogenization buffer (20 mM HEPES, 70 mM sucrose, 220 mM mannitol, 1 mM EDTA, and 0.5 mM PMSF, pH 7.6). After two spins at 400 x g for 10 min at 4°C to remove cellular debris and nuclear fractions, the mitochondria were separated from the supernatant by centrifugation at 11,000 x g for 10 min at 4°C. Bradford assay was used to determine the protein concentration wherever necessary using RotiQuant (Roth GmbH, Cat No: K015.1). Proteins were separated by SDS-PAGE and transferred to PVDF membranes (Millipore) by semi-dry transfer using standard methods. The membranes were probed with the respective primary antibodies as descried in the reagents section. HRP-coupled secondary antibodies were applied to antigen-antibody complexes and detected by enhanced chemiluminescence on X-ray films.

Quantification and Statistical Analysis {#sec3.5}
---------------------------------------

Data are denoted as mean ± SEM. The exact sample sizes (n) are indicated in the figure legends. The calculation of mean ± SEM and the significance of the difference between groups was performed using Prism 5 software (GraphPad Software, San Diego, CA). The tests used were either unpaired non-parametric or paired non-parametric t tests and ANOVA analysis, unless otherwise noted.

Data and Software Availability {#sec3.6}
------------------------------

The Gene Expression Omnibus accession number for the RNA sequencing data reported in this paper is [GSE119775](ncbi-p:GSE119775){#intref0060}. (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119775>)
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